More than 250 representatives are coming together to not only network but also share their dedication to find the cure for Alzheimer's. This includes announcing a new partnership with UNLV.

A blood test for Alzheimer’s Disease a game-changer for patients and their families.

Detect Alzheimer's disease early with a groundbreaking blood test that could change the game for millions of people worldwide! This revolutionary diagnostic tool can identify the disease years before symptoms appear, giving patients and their families a head start on treatment and care. The FDA just cleared the first blood test for identifying patients with amyloid pathology associated with Alzheimer’s disease — and part of the research behind its approval was conducted by leading experts at the UNLV Department of Brain Health, with chair and renowned brain health researcher, Jefferson Kinney, PhD, our guest for today’s Show. In this video, we'll dive into the science behind this innovative test, how it works, and what it means for the future of Alzheimer's research and treatment. If you or a loved one is at risk for Alzheimer's, you won't want to miss this!

A new blood test is being called a game changer for helping diagnose Alzheimer’s. The new FDA-approved test, known as Lumipulse, detects the pTau217/Beta Amyloid 42 amyloids plaques in the brain, a hallmark of the disease.

BACE1, aka β-secretase, is infamous for its fateful snip of amyloid precursor protein that leads to the production of Aβ peptides. Yet this might not be the only way BACE1 eggs on Alzheimer’s pathogenesis. According to a study published February 26 in Neuron, the enzyme also cleaves protein subunits off GABAAR, a receptor that transmits inhibitory currents responsible for reining in neuronal activity.

On Sunday, the Alzheimer’s Association kicks off its international conference and there’s already buzz about a blood test that is between 85% and 90% accurate in identifying Alzheimer’s disease. Having an easy blood test could be game changing. Right now, the only way to confirm an Alzheimer’s diagnosis is with a costly PET scan or an invasive spinal puncture.

June is Alzheimer’s Awareness Month. We visit Cleveland Clinic Lou Ruvo Center for Brain Health to meet three people at the forefront of researching, patient advocacy, and treatment. They share what medications are currently available for patients and what they are learning about the disease. They also share information for the many people caring for a loved one with Alzheimer’s disease.

Right now, Nevada has the third-fastest rate of growth for Alzheimer’s disease. Between now and 2025, the number of Nevadans with dementia is expected to grow almost 31% from 49,000 to 64,000.